JP4594080B2 - 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の肝臓保護活性 - Google Patents
2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の肝臓保護活性 Download PDFInfo
- Publication number
- JP4594080B2 JP4594080B2 JP2004503029A JP2004503029A JP4594080B2 JP 4594080 B2 JP4594080 B2 JP 4594080B2 JP 2004503029 A JP2004503029 A JP 2004503029A JP 2004503029 A JP2004503029 A JP 2004503029A JP 4594080 B2 JP4594080 B2 JP 4594080B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hepatitis
- acid
- composition according
- hydroxybenzoylmussaenoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(CCC12)C1C(OC(C(*)C(C1*)O)OC1NO)OC=C2N Chemical compound CC(C)(CCC12)C1C(OC(C(*)C(C1*)O)OC1NO)OC=C2N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Addiction (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Description
(a)植物物質を公知の方法により粉末化し;
(b)水性アルコール抽出物を浸出により調製し;
(c)アルコール抽出物を常法により濃縮し;
(d)塩化エチレン、塩化メチレン、クロロホルムまたは酢酸エチルのような溶媒で抽出物を摩砕することにより、脂肪非極性成分を除去し;
(e)残留抽出物をシリカゲルに吸着させ;
(f)カラムクロマトグラフィーによる吸着抽出物からのアグヌシドの単離;
(g)肝臓保護活性
からなる、明細書に添付された式1の化合物の肝臓保護活性を提供する。
結晶化合物として得られた1,mp148‐50℃,M+:496,UV‐260nm(MeOH)nm,(KBr)スペクトルは3400,1700,1640および1610cm−1で吸収を示した。1H NMR(200MHz,CD3OD)δ5.48(J3,H‐1),7.09(s,H‐3),25(m,H‐5),2.19(m,H‐9),1.25(s,H‐10),6.80(dd,2,7,H‐3″,H‐5″),7.83(d,2,7,H‐2″,6″),4.99(d,7,H‐1′),4.69(d,J7,H‐2″).13C NMR:122.99(C‐1),133.67(C‐2″,6″),116.92(C‐3″,5″),164.11(C‐4″),168.08(CO),95.83(C‐1),151.98(C‐3),116.92(C‐4),30.96(C‐5),31.98(C‐6),42.04(C‐7),80.64(C‐8),53.19(C‐9),25.15(C‐10),170.71(C‐11),98.64(C‐1′),76.85(C‐2′),75.70(C‐3′),72.55(C‐4′),79.30(C‐5′),63.54(C‐6′).
1.植物物質を公知の方法により粉末化し、
2.水性アルコール抽出物を浸出により調製し、
3.アルコール抽出物を常法により濃縮し、
4.塩化エチレン、塩化メチレン、クロロホルムまたは酢酸エチルのような溶媒で抽出物を摩砕することにより、脂肪非極性成分を除去し、
5.残留抽出物をシリカゲルに吸着させ、
6.カラムクロマトグラフィーによる吸着抽出物からの2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の単離
からなる。
V.negundoの陰干し粉末葉を浸出により80%エタノール(4+x−3L)で抽出した。プールした抽出物を減圧下で1L以下の水性濃縮物に濃縮した。水性濃縮物を酢酸エチル(3×500ml)で洗浄し、更に400mlに濃縮した。シロップ状残渣をシリカゲル400gに吸着させ、室温で乾燥させた。スラリーをシリカゲルカラムにのせ、クロロホルム‐メタノール(9:1)の混合液で溶出させ、(033(2)としてコードされる)1(1.5g)を得た。
Vitex negundoの微粉砕葉(200g)を石油(60〜80°)(初回の抽出は1L、次いで2回の抽出は各々600ml)で3回抽出した。薬物から室温で溶媒を除去した。次いでそれをエタノール(初回の抽出は1L、次いで同溶媒で3回各々600ml)で抽出した。ロータリーフィルムエバポレーターでエタノールの蒸発により、(033としてコードされる)抽出物30gを得た。
033および033(2)は、肝毒素としてCCUを用いてげっ歯類で実験的に誘導された肝障害において、顕著な肝臓保護活性を示した。033および033(2)は、高レベルの血清GPT、GOT、ALP、ビリルビン、TGおよび肝臓ホモゲネート脂質過酸化を減少させ、GSHレベルを増加させた。033および033(2)はシリマリンとほぼ同程度に有効であり、高レベルのGTPを各々67.52&60.34%、GOTを58.91&58.05%、ALPを58.26&53.95%、ビリルビンを60.00&66.66%、TGを46.47&44.19%および肝臓ホモゲネートLPを55.71&45.85%およびGSHを61.42&45.56%減少させた。シリマリンの場合は各々58.44、51.63、52.26、57.50、41.30、62.05&60.15%であった(表1)。
ガラクトサミン(GalN)誘導性肝障害の実験動物の治療において、033および033(2)で観察された肝臓保護活性は、血清GPT、GOT、ビリルビン、ALPおよびTGで各々59.58&50.75、56.62&43.64、54.28&50.11、57.71&57.57、57.89&44.76%、肝臓ホモゲネート脂質過酸化(LP)およびGSHで各々67.51&38.65、66.56&48.10%であった。シリマリンの場合は各々57.38、55.40、60.00、53.54、46.17、69.59、67.18%であった(表2)。現行使用の植物と比較した本発明の利点は、肝臓保護活性に基づいている:
1.ネグンドシドは市販ハーブ肝臓保護剤シリマリンよりも強力である。
2.シリマリンは3成分の混合物であり、その相対的割合はバッチ毎に異なるが、ネグンドシドは純粋化合物である。
Claims (11)
- 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の単離工程を含む方法により植物Vitex negundoから得られた2′‐p‐ヒドロキシベンゾイルムッサエノシド酸を含んでなる、ヒトを含めた対象哺乳動物に於ける肝疾患症状の治療および/または予防用組成物であって、
上記2′‐p‐ヒドロキシベンゾイルムッサエノシド酸を場合により単独でまたは1種以上の製薬上の添加物と共に含んでなる上記組成物。 - 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の濃度が20〜200mg/kg体重の範囲である、請求項1に記載の組成物。
- 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の濃度が50mg/kg体重である、請求項2に記載の組成物。
- 治療の対象がヒトである、請求項1に記載の組成物。
- 組成物が、単独でまたは製薬上許容されるキャリアと共に用いられる、請求項1に記載の組成物。
- 組成物が、製薬上許容される添加物、キャリア、希釈物、溶媒、フィラー、滑沢剤、賦形剤、結合剤または安定剤と共に対象へ投与される、請求項1に記載の組成物。
- 組成物が、経口、または臨床上/医学上許容される方法で投与される、請求項1に記載の組成物。
- ヒトのための投与量が5mg/kg体重である、請求項1に記載の組成物。
- 投与量が摂取上安全であり、いかなる副作用も有しない、請求項1に記載の組成物。
- 粉末、錠剤、カプセル、シロップ、顆粒、エマルジョン、エアゾルおよびビーズからなる群より選択される様々な物理的形態にある、請求項1〜9のいずれか一項に記載の組成物。
- 肝硬変、ガラクトース血症、血管腫、血色素症、A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎、G型肝炎、アルコール性肝疾患、自己免疫性肝炎、肝臓の癌、胆道閉鎖症、I型糖原病、α‐1‐抗トリプシン欠損症、Alagille症候群、バイラー病、カロリ病、脂肪肝、原発胆汁性肝硬変、硬化性胆管炎または赤芽球増殖性プロトポルフィリン症に有用である、請求項1に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37930302P | 2002-05-10 | 2002-05-10 | |
US60/379,303 | 2002-05-10 | ||
PCT/IB2003/001808 WO2003094946A1 (en) | 2002-05-10 | 2003-05-09 | Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005531551A JP2005531551A (ja) | 2005-10-20 |
JP4594080B2 true JP4594080B2 (ja) | 2010-12-08 |
Family
ID=29420507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004503029A Expired - Fee Related JP4594080B2 (ja) | 2002-05-10 | 2003-05-09 | 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の肝臓保護活性 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7259148B2 (ja) |
EP (1) | EP1503773B9 (ja) |
JP (1) | JP4594080B2 (ja) |
CN (1) | CN100391465C (ja) |
AU (1) | AU2003224361B2 (ja) |
DE (1) | DE60336549D1 (ja) |
WO (1) | WO2003094946A1 (ja) |
ZA (1) | ZA200409048B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7338674B2 (en) * | 2004-12-23 | 2008-03-04 | Council Of Scientific And Industrial Research | Anti-arthritic herbal composition and method thereof |
CN102391332B (zh) * | 2011-09-20 | 2014-09-24 | 华中科技大学 | 一种保肝化合物及其制备方法和用途 |
BR102017003318A2 (pt) * | 2017-02-17 | 2018-10-30 | Aché Laboratórios Farmacêuticos S.A. | compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6943282B1 (en) * | 1983-09-26 | 2005-09-13 | Mycogen Plant Science, Inc. | Insect resistant plants |
JPS6037999A (ja) * | 1983-08-09 | 1985-02-27 | Osaka Chem Lab | 肝障害有効薬物の簡易試験法 |
US4889918A (en) * | 1983-12-21 | 1989-12-26 | Boehringer Mannheim Gmbh | Protein tokin from bacillus thiringiensis which is toxic to coleoptera |
US5338544A (en) * | 1987-04-16 | 1994-08-16 | Ecogen Inc. | CryIIB protein, insecticidal compositions and methods of use thereof |
US5187091A (en) * | 1990-03-20 | 1993-02-16 | Ecogen Inc. | Bacillus thuringiensis cryiiic gene encoding toxic to coleopteran insects |
EP0505572A4 (en) * | 1990-10-09 | 1993-03-10 | Tsumura & Co. | Iridoide derivative and its use as medicine |
ES2124738T3 (es) * | 1991-08-02 | 1999-02-16 | Mycogen Corp | Nuevo microorganismo e insecticida. |
US5962765A (en) * | 1991-08-08 | 1999-10-05 | Boyce Thompson Institute For Plant Research, Inc. | Molecular cloning of a complimentary DNA sequence encoding a cuticle degrading protease produced by entomopathogenic fungi |
US5763568A (en) * | 1992-01-31 | 1998-06-09 | Zeneca Limited | Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders |
US5712248A (en) * | 1992-02-27 | 1998-01-27 | Sandoz Ltd. | Method of controlling insect with novel insecticidal protein |
KR100218052B1 (ko) * | 1992-07-15 | 1999-09-01 | 이병언 | B형 간염 바이러스의 복제를 억제하는 약학적 제제 |
US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
WO1995017515A1 (en) * | 1993-12-23 | 1995-06-29 | University Technologies International Inc. | Methods of expressing proteins in insect cells and methods of killing insects |
US5759538A (en) * | 1995-03-31 | 1998-06-02 | Monsanto Company | Bacillus thuringiensis apr and npr genes, apr and npr B.t. strains, and method of use |
US5639454A (en) * | 1995-04-06 | 1997-06-17 | Board Of Trustees Operating Michigan State University | Recombinant baculovirus with broad host range |
US5756459A (en) * | 1995-06-07 | 1998-05-26 | Fmc Corporation | Insecticidally effective peptides isolatable from phidippus spider venom |
US5924664A (en) * | 1997-03-12 | 1999-07-20 | Ergo View Technologies Corp. | Keyboard support mechanism |
US6664236B2 (en) * | 2002-03-19 | 2003-12-16 | Council Of Scientific And Industrial Research | Synergistic composition of bioactive fraction isolated from barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof |
-
2003
- 2003-05-09 DE DE60336549T patent/DE60336549D1/de not_active Expired - Lifetime
- 2003-05-09 EP EP03720787A patent/EP1503773B9/en not_active Expired - Fee Related
- 2003-05-09 JP JP2004503029A patent/JP4594080B2/ja not_active Expired - Fee Related
- 2003-05-09 CN CNB038105489A patent/CN100391465C/zh not_active Expired - Fee Related
- 2003-05-09 AU AU2003224361A patent/AU2003224361B2/en not_active Ceased
- 2003-05-09 WO PCT/IB2003/001808 patent/WO2003094946A1/en active Application Filing
- 2003-05-12 US US10/436,321 patent/US7259148B2/en not_active Expired - Lifetime
-
2004
- 2004-11-09 ZA ZA200409048A patent/ZA200409048B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1503773B1 (en) | 2011-03-30 |
AU2003224361B2 (en) | 2008-01-31 |
JP2005531551A (ja) | 2005-10-20 |
WO2003094946A1 (en) | 2003-11-20 |
US7259148B2 (en) | 2007-08-21 |
CN1652808A (zh) | 2005-08-10 |
DE60336549D1 (de) | 2011-05-12 |
EP1503773A1 (en) | 2005-02-09 |
AU2003224361A1 (en) | 2003-11-11 |
US20040014684A1 (en) | 2004-01-22 |
EP1503773B9 (en) | 2012-01-25 |
CN100391465C (zh) | 2008-06-04 |
ZA200409048B (en) | 2006-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Al-Snafi | Chemical constituents and pharmacological effects of lepidium sativum | |
US6210680B1 (en) | Method for the prevention and treatment of chronic venous insufficiency | |
JP2009501708A (ja) | チョウセンアザミ抽出物、その使用及びそれを含む配合物 | |
KR101632369B1 (ko) | 센텔라 아시아티카로부터 고순도 아시아티코사이드 조성물의 제조 방법 및 그 사용 방법 | |
US20190105365A1 (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
Küçükboyacı et al. | In vivo Anti-Inflammatory and Antinociceptive Activities of the Extracts and Chemical Constituents of an Endemic Turkish Plant, Salsola grandis. | |
HU195504B (en) | Process for preparing sylibinine free of isosylibinine | |
JP4594080B2 (ja) | 2′‐p‐ヒドロキシベンゾイルムッサエノシド酸の肝臓保護活性 | |
Jain et al. | Effects of Tephrosia purpurea and Momordica dioica on streptozotocin-induced diabetic nephropathy in rats | |
JPS6212791A (ja) | オウギサポニン、その単離法およびその用途 | |
Ram et al. | Past and present scenario of hepatoprotectants | |
EP1509223B1 (en) | Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin | |
EP1526860A2 (en) | Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof | |
Aswini et al. | Role of phytochemicals in diuresis management | |
KR20040019365A (ko) | (-)-세코이소라리시레시놀을 포함하는 약학 조성물 | |
KR0137422B1 (ko) | 아랄로사이드 a를 유효 성분으로 하는 위장 질환 치료제 | |
EP2649991B1 (en) | Extracts and isolated compounds from Euphorbia granulata Forrsk. for treatment of ulcerative colitis | |
CN115869356B (zh) | 一种具有抗旋毛虫药用的倒钩刺活性部位的制备 | |
Sudheer et al. | Phytochemistry and Pharmacology of Boerhavia diffusa Linn. | |
Rashid | Evaluation of pharmacological potentials and biological activities of Periploca aphylla Decne. and Fagonia olivieri DC. | |
JPS6259119B2 (ja) | ||
RAJENDIRAN et al. | THERAPEUTIC POTENTIAL OF MIMOSA PUDICA-A REVIEW | |
Bhajipale | International Journal Of Ayurvedic And Herbal Medicine 2: 3 (2012) 598: 603 | |
WO2003080081A2 (en) | Synergistic composition of trans-tetracos-15-enoic acid and apocynin and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100215 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100413 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100420 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100820 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100916 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4594080 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |